Partnering talks led to Biogen’s $800M Nightstar buyout as players clustered around the hot deal table for gene therapies

Partnering talks led to Biogen’s $800M Nightstar buyout as players clustered around the hot deal table for gene therapies

Source: 
Endpoints
snippet: 

Anyone looking for some insight into just how hot gene therapies have become should turn their attention today to the behind-the-scenes negotiations that went into Biogen’s $800 million deal to buy Nightstar Therapeutics $NITE.